Antiandrogen and hormonal treatment of acne (Q41545505)

3 October 2017

1 reference

title

Antiandrogen and hormonal treatment of acne (English)

1 reference

3 October 2017

J. C. Shaw

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9238337

9 November 2024

language of work or name

1 reference

1 October 1996

1 reference

3 October 2017

October 1996

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9238337

full work available at URL

9 November 2024

https://api.elsevier.com/content/article/PII:S0733863505704058?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0733-8635(05)70405-8

https://api.elsevier.com/content/article/PII:S0733863505704058?httpAccept=text/plain

9 November 2024

1 reference

https://api.crossref.org/works/10.1016/S0733-8635(05)70405-8

9 November 2024

1 reference

3 October 2017

volume

14

1 reference

3 October 2017

issue

4

1 reference

3 October 2017

page(s)

803-811

1 reference

Dissociation between cortisol and adrenal androgen secretion in patients receiving alternate day prednisone therapy

3 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Gonadotropin-releasing hormone and its analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Efficacy and clinical profile of a new oral contraceptive containing norgestimate. U.S. clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Comparative effects of cyproterone acetate or a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Predictors of clinical response in hirsute women treated with spironolactone

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Effects of a low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Treatment of hirsutism with the pure antiandrogen flutamide

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial**Supported in part by Schering-Plough, Pointe-Claire, Québec, Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Safety and efficacy of a triphasic oral contraceptive containing desogestrel: results of three multicenter trials

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

The treatment of hirsutism with a combination of desogestrel and ethinyl oestradiol

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Hair growth effects of oral administration of finasteride, a steroid 5 alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Comparison of the efficacy of spironolactone**Spironolactone (Aldactone; Searle, Chicago, IL). versus flutamide††Flutamide (Eulexin; Schering Plough Laboratories, Heist, Belgium). in the treatment of hirsutism‡‡Presented in part at the 3rd Wo

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Oral spironolactone improves acne vulgaris and reduces sebum excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Tolerance of spironolactone

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Fulminant hepatitis due to cyproterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Evidence for the Importance of Peripheral Tissue Events in the Development of Hirsutism in Polycystic Ovary Syndrome*

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Letter: Breast cancer associated with administration of spironolactone

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Adrenal abnormalities in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Treatment of hirsutism in women with flutamide

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Anti-androgen treatment in women with acne: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Flutamide in the treatment of hirsutism

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Oral spironolactone: an effective treatment for acne vulgaris in women

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Comparison of Sequential Cyproterone Acetate/Estrogen Versus Spironolactone/Oral Contraceptive in the Treatment of Hirsutism

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

1 reference

7 January 2021

Effect of daily and alternate day low dose prednisone on serum cortisol and adrenal androgens in hirsute women

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Oral contraceptives and breast cancer. Review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinyloestradiol

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Spironolactone in dermatologic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Clinical and Hormonal Effects of Chronic Gonadotropin Releasing Hormone Agonist Treatment in Polycystic Ovarian Disease*

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Hepatotoxicity complicating flutamide treatment of hirsutism

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Three cases of hepatocellular carcinoma among cyproterone users

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Fatal and Nonfatal Hepatotoxicity Associated with Flutamide

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970405-8

7 January 2021

Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism

4

1 reference

https://api.crossref.org/works/10.1016/S0733-8635(05)70405-8

Spironolactone and cimetidine in treatment of acne

9 November 2024

23

1 reference

https://api.crossref.org/works/10.1016/S0733-8635(05)70405-8

Fatal fulminant hepatitis from cyproterone acetate

9 November 2024

25

1 reference

https://api.crossref.org/works/10.1016/S0733-8635(05)70405-8

Oral contraceptive use and breast cancer risk: a meta-analysis of variations with age at diagnosis, parity and total duration of oral contraceptive use

9 November 2024

43

1 reference

https://api.crossref.org/works/10.1016/S0733-8635(05)70405-8

9 November 2024

Identifiers

1 reference

3 October 2017

1 reference